Brokers Set Expectations for NTLA FY2027 Earnings

Key Points

• Brookline Capital Markets lowered its FY2027 EPS estimate for Intellia Therapeutics to $0.92 from $0.97, while forecasting $5.15 per share for FY2028.
• Intellia reported a quarterly loss of $0.91 per share, worse than the $0.80 loss analysts expected; revenue of $7.16 million also fell short of the $9.74 million estimate and declined 47.8% year over year.
• Analyst views are mixed: MarketBeat lists a consensus rating of Hold and an average price target of $21.05, with 10 Buy/Strong Buy, seven Hold, and four Sell ratings.

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Research analysts at Brookline Capital Markets cut their FY2027 earnings estimates for shares of Intellia Therapeutics in a note issued to investors on Thursday, November 5th. Brookline Capital Markets analyst L. Cann now anticipates that the company will post earnings of $0.92 per share for the year, down from their previous estimate of $0.97. The consensus estimate for Intellia Therapeutics' current full-year earnings is ($3.21) per share. Brookline Capital Markets also issued estimates for Intellia Therapeutics' FY2028 earnings at $5.15 EPS.

Several other research firms have also recently issued reports on NTLA. HC Wainwright reaffirmed a "buy" rating and set a $25.00 price objective on shares of Intellia Therapeutics in a research report on Wednesday, September 9th. Citizens Jmp reiterated a "market outperform" rating and issued a $30.00 price objective on shares of Intellia Therapeutics in a report on Wednesday, September 9th. Citigroup reissued a "market outperform" rating on shares of Intellia Therapeutics in a research report on Tuesday, August 25th. Wolfe Research cut Intellia Therapeutics from a "peer perform" rating to an "underperform" rating and set a $9.00 target price for the company. in a research note on Wednesday, July 15th. Finally, Evercore upgraded Intellia Therapeutics from a "hold" rating to an "outperform" rating and set a $24.00 target price for the company in a research note on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, seven have issued a Hold rating and four have given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $21.05.

Intellia Therapeutics Price Performance

Intellia Therapeutics stock opened at $11.35 on Monday. Intellia Therapeutics has a 1-year low of $7.95 and a 1-year high of $18.48. The stock has a market cap of $1.59 billion, a PE ratio of -3.39 and a beta of 1.83. The stock's fifty day moving average is $12.09 and its two-hundred day moving average is $13.05.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported ($0.91) EPS for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.11). The firm had revenue of $7.16 million for the quarter, compared to analyst estimates of $9.74 million. Intellia Therapeutics had a negative return on equity of 63.29% and a negative net margin of 805.75%. The business's revenue for the quarter was down 47.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.92) EPS.

Insider Buying and Selling

In related news, CEO John M. Leonard sold 9,000 shares of Intellia Therapeutics stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $11.99, for a total transaction of $107,910.00. Following the sale, the chief executive officer directly owned 1,138,064 shares in the company, valued at $13,645,387.36. This trade represents a 0.78% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 3.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Intellia Therapeutics

Several large investors have recently bought and sold shares of NTLA. Nykredit A S acquired a new stake in shares of Intellia Therapeutics during the second quarter worth about $33,000. Freestone Grove Partners LP purchased a new stake in shares of Intellia Therapeutics in the 2nd quarter valued at about $33,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Intellia Therapeutics in the 2nd quarter valued at about $34,000. Farther Finance Advisors LLC boosted its position in shares of Intellia Therapeutics by 289.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,144 shares of the company's stock valued at $26,000 after purchasing an additional 1,594 shares during the period. Finally, Parallel Advisors LLC boosted its position in shares of Intellia Therapeutics by 267.0% in the 3rd quarter. Parallel Advisors LLC now owns 2,268 shares of the company's stock valued at $27,000 after purchasing an additional 1,650 shares during the period. Institutional investors and hedge funds own 88.77% of the company's stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a biotechnology company focused on developing potentially curative treatments using CRISPR-based gene-editing technology. The company is working to create therapies that can modify disease-causing genes inside the body, with the goal of addressing the underlying causes of serious genetic diseases rather than treating only their symptoms.

Intellia's pipeline has included NTLA-2001, an investigational in vivo gene-editing therapy designed to reduce production of transthyretin for the treatment of transthyretin amyloidosis, and NTLA-2002, an investigational therapy intended to target hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.